The log-rank test indicated a significant association of mRNA levels with overall survival (OS) of lung cancer patients (P < 0.05), and the TIMELESS, RORA, PER2, and CRY2 expressions were significantly correlated with progression-free survival (PFS) in lung cancer patients (P < 0.05). Here, PER2 is linked to lung carcinoma.